Skip to main content

Table 2 Parameters applied in the Markov model, their distributions and the values used to estimate the distributions

From: Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis

Parameter

Value (variation)

Distribution

Distribution values used in PSA

Mean (SE)

Source

Hazard ratios

 Effect of intervention (95% CI)

0.74 (0.53–1.03)

Lognormal

0.74 (0.17)

[26]

 T2D-specific mortality risk (95% CI)

HR 2.47 (2.42–3.06) (women)

Lognormal

2.47 (0.04)

[27]

HR 1.93 (1.79–2.07) (men)

 

1.93 (0.05)

 

 Mortality risk associated with T2D with complications

HR 2.36 (1.70–3.29)

Lognormal

2.36 (0.41)

[28]

 All-cause mortalitya

Based on age and gender

–

–

[29]

Utilities

 Baseline utilities (EQ-5D-3L)

Women

(Age, Utility, SE)

Beta

Alpha

(Age, value)

Women

Beta

(Age, value)

Women

[30]

30–44 0.906 (0.003)

 

30–44 8573

30–44, 889

 

45–54 0.865 (0.005)

 

45–54 4040

45–54, 631

 

55–64 0.810 (0.006)

 

55–64 3463

55–64, 812

 

65+  0.770 (0.008)

 

65+  2130

65+  636

 

Men

(Age, Utility, SE)

 

Men

Men

30–44 0.917 (0.003)

 

30–44 7755

30–44, 702

 

45–54 0.876 (0.005)

 

45–54 3806

45–54, 539

 

55–64 0.821 (0.006)

 

55–64 3351

55–64, 731

 

65+  0.781 (0.008)

 

65+  2087

65+  585

 Disutility of T2D (EQ-5D-3L) (SE)

0.041 (0.012)

Beta

Alpha

11.19

Beta

261.9

[31]

 Weighted disutility of T2D complications (EQ-5D-3L)b

0.119 (0.089–0.149)

Beta

0.119 (0.015)

Disutility values of individual complications [32,33,34,35,36]

Proportion of complications [37]

  1. aAll-cause mortality data is shown in additional file 7
  2. bFor variables without available confidence interval, a variation of ±25% has been used as an estimate. In these cases, SE has been calculated as:
  3. \( SE=\frac{Mean\ast 1.25- Mean\ast 0.75}{2\ast 1.96} \)